CLINICAL_TRIALS
trial_result
· 2021-11-09
Clinical Trial Update: Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens [Phase 1]
Summary
Phase 1 trial evaluating peptide targets for glioblastoma against novel cytomegalovirus antigens; study terminated with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Snippet
Sponsor: Eric Thompson, M.D. | Conditions: Glioblastoma, Glioblastoma Multiforme | Phase 1 | Status: TERMINATED | Results posted: 2021-11-09